Phase II Study of Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2009-2011

ABSTRACT

Sunitinib shows anti-tumor activity in a variety of human non-small cell lung tumor ex vivo models. Many Phases II and III clinical trials of sunitinib in several solid tumors are completed or still ongoing. So far, the efficacy of sunitinb has been confirmed by the phase III trial for imatinib-resistance or intolerance advanced gastrointestinal stromal tumor patients. And sutent was approved to effective by two phase II trials in advanced renal cell carcinoma patients after failure of immunotherapies, and one phase III trial in treatment-naive advanced renal carcinoma patients. Sunitinib (SUTENT ®) has been approved by U.S. Food and Drug Administration (FDA) for the treatment of advanced renal carcinoma patients and in gastrointestinal stromal tumor patients who are intolerant or progressed after imatinib mesylate. European Medicines Agency (EMEA) conditionally granted the marketing approval for the treatment of metastatic renal carcinoma patients after failure of immunotherapy. A phase II trial (A6181040 study) on non-small cell lung cancer patients treated with sunitinib alone showed anti-tumor activity. In 63 enrolled patients treated with 4/2 schedule (4 weeks treatment, then two weeks interruption), 7 patients are confirmed partial response (overall response rate, 11%), and median progress-free time is 14.3 weeks. Presently, a phase III study is underway on non-small cell lung cancer patients followed by and now is under recruiting. Non-small cell lung cancer cells often over-express vascular endothelial growth factor (VEGF) receptors. Besides, the expression of the VEGF ligands is also correlated with increased tumor angiogenesis, as well as shortened survival time. One study treated with VEGF-directed monoclonal antibody (bevacizumab) and VEGFR and platelet-derived growth factor receptor (PDGFR) small molecule inhibitors (sunitinib) showed that some non-small cell lung cancer patients are with anti-tumor activity. The chemotherapy drugs, such as docetaxel and platinum-based compounds, were with evidence that they have direct cytotoxicity to cancer cells. Therefore, the investigators are paying attention to the efficacy of combining sunitinib and conventional chemotherapy in this study. The study is designed as first line of salvage therapy on metastatic or unresectable non-small cell lung cancer patients. The main goals of this study is to evaluate the overall response rate (ORR) and duration of response (DR) of sunitinib in combinational with docetaxel and cisplatin in chemotherapy-naive advanced or metastatic non-small cell lung cancer patients. Detailed Description Study Design This is a single-center, open-label, phase II clinical trial. Simon two-stage analysis is adopted.The sample size in the first stage is 16 patients. The length of study is approximately 24 months. The targeted subject is patient with metastatic or unresectable non-small cell lung cancer. Study Endpoints Primary Endpoint Assess the response rate of sunitinib, docetaxel and cisplatin in the treatment of naïve chemotherapy metastatic or unresectable non-small cell lung cancer patients. Secondary Endpoint 1. Time to disease progression (defined as the time period from the start of investigated medication to investigator assessed disease progression) at the end of study. 2. Duration of survival (defined as the time period from the start of investigated medication to death). 3. Safety profile of sunitinib in combination with docetaxel and cisplatin: cardiac toxicity assessed in accordance with National Cancer Institute Common Toxicity Criteria (version 3.0). The incidence of serious adverse events related to the treatment and the incidence of specific adverse events (serious and non-serious) such as gastro-intestinal perforation, wound healing complication, bleeding, hypertension, arterial thromboembolic events and proteinuria will be investigated. NCI-CTCAE criteria (version 3.0) will be used. More... »

URL

https://clinicaltrials.gov/show/NCT01019798

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Sunitinib shows anti-tumor activity in a variety of human non-small cell lung tumor ex vivo models. Many Phases II and III clinical trials of sunitinib in several solid tumors are completed or still ongoing. So far, the efficacy of sunitinb has been confirmed by the phase III trial for imatinib-resistance or intolerance advanced gastrointestinal stromal tumor patients. And sutent was approved to effective by two phase II trials in advanced renal cell carcinoma patients after failure of immunotherapies, and one phase III trial in treatment-naive advanced renal carcinoma patients. Sunitinib (SUTENT \u00ae) has been approved by U.S. Food and Drug Administration (FDA) for the treatment of advanced renal carcinoma patients and in gastrointestinal stromal tumor patients who are intolerant or progressed after imatinib mesylate. European Medicines Agency (EMEA) conditionally granted the marketing approval for the treatment of metastatic renal carcinoma patients after failure of immunotherapy. A phase II trial (A6181040 study) on non-small cell lung cancer patients treated with sunitinib alone showed anti-tumor activity. In 63 enrolled patients treated with 4/2 schedule (4 weeks treatment, then two weeks interruption), 7 patients are confirmed partial response (overall response rate, 11%), and median progress-free time is 14.3 weeks. Presently, a phase III study is underway on non-small cell lung cancer patients followed by and now is under recruiting. Non-small cell lung cancer cells often over-express vascular endothelial growth factor (VEGF) receptors. Besides, the expression of the VEGF ligands is also correlated with increased tumor angiogenesis, as well as shortened survival time. One study treated with VEGF-directed monoclonal antibody (bevacizumab) and VEGFR and platelet-derived growth factor receptor (PDGFR) small molecule inhibitors (sunitinib) showed that some non-small cell lung cancer patients are with anti-tumor activity. The chemotherapy drugs, such as docetaxel and platinum-based compounds, were with evidence that they have direct cytotoxicity to cancer cells. Therefore, the investigators are paying attention to the efficacy of combining sunitinib and conventional chemotherapy in this study. The study is designed as first line of salvage therapy on metastatic or unresectable non-small cell lung cancer patients. The main goals of this study is to evaluate the overall response rate (ORR) and duration of response (DR) of sunitinib in combinational with docetaxel and cisplatin in chemotherapy-naive advanced or metastatic non-small cell lung cancer patients.\n\nDetailed Description\nStudy Design This is a single-center, open-label, phase II clinical trial. Simon two-stage analysis is adopted.The sample size in the first stage is 16 patients. The length of study is approximately 24 months. The targeted subject is patient with metastatic or unresectable non-small cell lung cancer. Study Endpoints Primary Endpoint Assess the response rate of sunitinib, docetaxel and cisplatin in the treatment of na\u00efve chemotherapy metastatic or unresectable non-small cell lung cancer patients. Secondary Endpoint 1. Time to disease progression (defined as the time period from the start of investigated medication to investigator assessed disease progression) at the end of study. 2. Duration of survival (defined as the time period from the start of investigated medication to death). 3. Safety profile of sunitinib in combination with docetaxel and cisplatin: cardiac toxicity assessed in accordance with National Cancer Institute Common Toxicity Criteria (version 3.0). The incidence of serious adverse events related to the treatment and the incidence of specific adverse events (serious and non-serious) such as gastro-intestinal perforation, wound healing complication, bleeding, hypertension, arterial thromboembolic events and proteinuria will be investigated. NCI-CTCAE criteria (version 3.0) will be used.", 
    "endDate": "2011-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01019798", 
    "keywords": [
      "Phase II", 
      "salvage therapy", 
      "sunitinib", 
      "docetaxel", 
      "platinum", 
      "non small cell lung cancer", 
      "anti-tumor activity", 
      "ex vivo model", 
      "clinical trial", 
      "solid tumor", 
      "efficacy", 
      "Phase III trial", 
      "imatinib resistance", 
      "gastrointestinal stromal tumor", 
      "Sutent", 
      "trial", 
      "renal cell carcinoma patient", 
      "failure", 
      "immunotherapy", 
      "renal carcinoma", 
      "United State Food and Drug Administration", 
      "intolerant", 
      "imatinib mesylate", 
      "medicine", 
      "marketing", 
      "phase II trial", 
      "non-small cell lung cancer patient", 
      "enrolled patient", 
      "Appointment and Schedule", 
      "interruption", 
      "patient", 
      "partial response", 
      "overall response rate", 
      "free time", 
      "Phase III study", 
      "non-small cell lung cancer cell", 
      "Vascular Endothelial Growth Factor A", 
      "receptor", 
      "expression", 
      "vascular endothelial growth", 
      "tumor angiogenesis", 
      "survival time", 
      "bevacizumab", 
      "vascular endothelial growth factorR", 
      "Platelet-Derived Growth Factor Receptor", 
      "small molecule inhibitor", 
      "chemotherapy drug", 
      "evidence", 
      "direct cytotoxicity", 
      "cancer cell", 
      "conventional chemotherapy", 
      "first line", 
      "main goal", 
      "duration", 
      "cisplatin", 
      "study design", 
      "single center", 
      "Phase II clinical trial", 
      "two-stage", 
      "sample size", 
      "first stage", 
      "Non-Small-Cell Lung Carcinoma", 
      "study endpoint", 
      "primary endpoint", 
      "response rate", 
      "na\u00efve", 
      "endpoint", 
      "disease progression", 
      "time period", 
      "start", 
      "medication", 
      "survival", 
      "death", 
      "safety profile", 
      "cardiac toxicity", 
      "accordance", 
      "National Cancer Institute", 
      "toxicity", 
      "version", 
      "incidence", 
      "serious adverse event", 
      "adverse event", 
      "perforation", 
      "wound healing", 
      "hypertension", 
      "thromboembolic event", 
      "proteinuria", 
      "criterion"
    ], 
    "name": "Phase II Study of Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01019798"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00008.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.410513.2", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.412897.1", 
        "type": "Organization"
      }
    ], 
    "startDate": "2009-01-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1016/j.ejca.2009.06.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009432072"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11318860-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015837735", 
          "https://doi.org/10.2165/11318860-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605346", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036372309", 
          "https://doi.org/10.1038/sj.bjc.6605346"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa011954", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052159806"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3816/clc.2004.n.029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052655948"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/cbt.8.21.9886", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072295374"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075221300", 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01019798"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01019798'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01019798'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01019798'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01019798'


 

This table displays all metadata directly associated to this object as RDF triples.

131 TRIPLES      16 PREDICATES      111 URIs      97 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01019798 schema:about anzsrc-for:3142
2 schema:description Sunitinib shows anti-tumor activity in a variety of human non-small cell lung tumor ex vivo models. Many Phases II and III clinical trials of sunitinib in several solid tumors are completed or still ongoing. So far, the efficacy of sunitinb has been confirmed by the phase III trial for imatinib-resistance or intolerance advanced gastrointestinal stromal tumor patients. And sutent was approved to effective by two phase II trials in advanced renal cell carcinoma patients after failure of immunotherapies, and one phase III trial in treatment-naive advanced renal carcinoma patients. Sunitinib (SUTENT ®) has been approved by U.S. Food and Drug Administration (FDA) for the treatment of advanced renal carcinoma patients and in gastrointestinal stromal tumor patients who are intolerant or progressed after imatinib mesylate. European Medicines Agency (EMEA) conditionally granted the marketing approval for the treatment of metastatic renal carcinoma patients after failure of immunotherapy. A phase II trial (A6181040 study) on non-small cell lung cancer patients treated with sunitinib alone showed anti-tumor activity. In 63 enrolled patients treated with 4/2 schedule (4 weeks treatment, then two weeks interruption), 7 patients are confirmed partial response (overall response rate, 11%), and median progress-free time is 14.3 weeks. Presently, a phase III study is underway on non-small cell lung cancer patients followed by and now is under recruiting. Non-small cell lung cancer cells often over-express vascular endothelial growth factor (VEGF) receptors. Besides, the expression of the VEGF ligands is also correlated with increased tumor angiogenesis, as well as shortened survival time. One study treated with VEGF-directed monoclonal antibody (bevacizumab) and VEGFR and platelet-derived growth factor receptor (PDGFR) small molecule inhibitors (sunitinib) showed that some non-small cell lung cancer patients are with anti-tumor activity. The chemotherapy drugs, such as docetaxel and platinum-based compounds, were with evidence that they have direct cytotoxicity to cancer cells. Therefore, the investigators are paying attention to the efficacy of combining sunitinib and conventional chemotherapy in this study. The study is designed as first line of salvage therapy on metastatic or unresectable non-small cell lung cancer patients. The main goals of this study is to evaluate the overall response rate (ORR) and duration of response (DR) of sunitinib in combinational with docetaxel and cisplatin in chemotherapy-naive advanced or metastatic non-small cell lung cancer patients. Detailed Description Study Design This is a single-center, open-label, phase II clinical trial. Simon two-stage analysis is adopted.The sample size in the first stage is 16 patients. The length of study is approximately 24 months. The targeted subject is patient with metastatic or unresectable non-small cell lung cancer. Study Endpoints Primary Endpoint Assess the response rate of sunitinib, docetaxel and cisplatin in the treatment of naïve chemotherapy metastatic or unresectable non-small cell lung cancer patients. Secondary Endpoint 1. Time to disease progression (defined as the time period from the start of investigated medication to investigator assessed disease progression) at the end of study. 2. Duration of survival (defined as the time period from the start of investigated medication to death). 3. Safety profile of sunitinib in combination with docetaxel and cisplatin: cardiac toxicity assessed in accordance with National Cancer Institute Common Toxicity Criteria (version 3.0). The incidence of serious adverse events related to the treatment and the incidence of specific adverse events (serious and non-serious) such as gastro-intestinal perforation, wound healing complication, bleeding, hypertension, arterial thromboembolic events and proteinuria will be investigated. NCI-CTCAE criteria (version 3.0) will be used.
3 schema:endDate 2011-12-01T00:00:00Z
4 schema:keywords Appointment and Schedule
5 National Cancer Institute
6 Non-Small-Cell Lung Carcinoma
7 Phase II
8 Phase II clinical trial
9 Phase III study
10 Phase III trial
11 Platelet-Derived Growth Factor Receptor
12 Sutent
13 United State Food and Drug Administration
14 Vascular Endothelial Growth Factor A
15 accordance
16 adverse event
17 anti-tumor activity
18 bevacizumab
19 cancer cell
20 cardiac toxicity
21 chemotherapy drug
22 cisplatin
23 clinical trial
24 conventional chemotherapy
25 criterion
26 death
27 direct cytotoxicity
28 disease progression
29 docetaxel
30 duration
31 efficacy
32 endpoint
33 enrolled patient
34 evidence
35 ex vivo model
36 expression
37 failure
38 first line
39 first stage
40 free time
41 gastrointestinal stromal tumor
42 hypertension
43 imatinib mesylate
44 imatinib resistance
45 immunotherapy
46 incidence
47 interruption
48 intolerant
49 main goal
50 marketing
51 medication
52 medicine
53 naïve
54 non small cell lung cancer
55 non-small cell lung cancer cell
56 non-small cell lung cancer patient
57 overall response rate
58 partial response
59 patient
60 perforation
61 phase II trial
62 platinum
63 primary endpoint
64 proteinuria
65 receptor
66 renal carcinoma
67 renal cell carcinoma patient
68 response rate
69 safety profile
70 salvage therapy
71 sample size
72 serious adverse event
73 single center
74 small molecule inhibitor
75 solid tumor
76 start
77 study design
78 study endpoint
79 sunitinib
80 survival
81 survival time
82 thromboembolic event
83 time period
84 toxicity
85 trial
86 tumor angiogenesis
87 two-stage
88 vascular endothelial growth
89 vascular endothelial growth factorR
90 version
91 wound healing
92 schema:name Phase II Study of Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer
93 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01019798
94 schema:sdDatePublished 2019-03-07T15:23
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher Ne65707033b70430d8e5e074f1d467af5
97 schema:sponsor https://www.grid.ac/institutes/grid.410513.2
98 https://www.grid.ac/institutes/grid.412897.1
99 schema:startDate 2009-01-01T00:00:00Z
100 schema:subjectOf sg:pub.10.1038/sj.bjc.6605346
101 sg:pub.10.2165/11318860-000000000-00000
102 https://app.dimensions.ai/details/publication/pub.1075221300
103 https://doi.org/10.1016/j.ejca.2009.06.005
104 https://doi.org/10.1056/nejmoa011954
105 https://doi.org/10.3816/clc.2004.n.029
106 https://doi.org/10.4161/cbt.8.21.9886
107 schema:url https://clinicaltrials.gov/show/NCT01019798
108 sgo:license sg:explorer/license/
109 sgo:sdDataset clinical_trials
110 rdf:type schema:MedicalStudy
111 Ne65707033b70430d8e5e074f1d467af5 schema:name Springer Nature - SN SciGraph project
112 rdf:type schema:Organization
113 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
114 rdf:type schema:DefinedTerm
115 sg:pub.10.1038/sj.bjc.6605346 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036372309
116 https://doi.org/10.1038/sj.bjc.6605346
117 rdf:type schema:CreativeWork
118 sg:pub.10.2165/11318860-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015837735
119 https://doi.org/10.2165/11318860-000000000-00000
120 rdf:type schema:CreativeWork
121 https://app.dimensions.ai/details/publication/pub.1075221300 schema:CreativeWork
122 https://doi.org/10.1016/j.ejca.2009.06.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009432072
123 rdf:type schema:CreativeWork
124 https://doi.org/10.1056/nejmoa011954 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052159806
125 rdf:type schema:CreativeWork
126 https://doi.org/10.3816/clc.2004.n.029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052655948
127 rdf:type schema:CreativeWork
128 https://doi.org/10.4161/cbt.8.21.9886 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072295374
129 rdf:type schema:CreativeWork
130 https://www.grid.ac/institutes/grid.410513.2 schema:Organization
131 https://www.grid.ac/institutes/grid.412897.1 schema:Organization
 




Preview window. Press ESC to close (or click here)


...